The A.I. Daily
Lunit, Summit team up on AI biomarkers for cancer drug
Korean medical AI firm Lunit will work with Summit Therapeutics, applying its Lunit Scope IO pathology platform to find biomarkers tied to treatment response for the dual-antibody drug ibonesimab, helping select likely responders. Summit is developing the PD-1/VEGF candidate globally.